Hematology · Pediatrics · Infectious Disease · 2 h ago
EBV-infected cell lineage linked to outcomes in pediatric lymphoproliferative disorders
A retrospective Japanese central pathology cohort study analyzed 36 children with Epstein-Barr virus-related lymphoproliferative disorders (EBV-LPD). EBV-T/NK-LPD had lower 5-year overall survival than EBV-B-LPD, and EBER double-staining identified the infected cell lineage, including in diagnostically challenging lesions.
- EBER double-staining identified the EBV-infected cell lineage.
- Five-year survival was lower in EBV-T/NK-LPD than EBV-B-LPD.
- The retrospective cohort included 36 children.
Researchers retrospectively analyzed pathology from 36 children with EBV-related lymphoproliferative disorders in the Japan Children’s Cancer Group between 2006 and 2021. The cohort focused on diagnostically challenging lesions that had not been definitively classified as lymphoma. EBER in situ hybridization double-staining was used to identify the EBV-infected cell lineage.
EBV infection was identified primarily in T/NK cells in 17 cases and in B cells in 16. Lymphoid follicle architecture was effaced in 89% of EBV-T/NK-LPD cases and 54% of EBV-B-LPD cases. Five-year overall survival was 59% for EBV-T/NK-LPD and 93% for EBV-B-LPD.
The findings suggest that identifying the infected cell lineage may help classify pediatric EBV-LPD and distinguish groups with different observed outcomes. The retrospective cohort was small, and the supplied abstract does not provide details on treatment or statistical uncertainty; the results support diagnostic and prognostic relevance but do not establish a change in clinical management.
In practice
For children with EBV-related lymphoproliferative disorders, EBER double-staining to establish whether infected cells are T/NK or B lineage may help resolve diagnostically challenging lesions and provide prognostic context. In this retrospective cohort of 36 children, five-year overall survival differed between the groups (59% for EBV-T/NK-LPD versus 93% for EBV-B-LPD). These findings support the potential value of lineage assessment, but the small cohort and lack of supplied treatment and uncertainty details mean they do not establish a management change.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
The Journal of Infectious Diseases: EBV-infected cell lineage by EBER double-staining as a diagnostic and prognostic clue in pediatric EBV-related lymphoproliferative disorders: a Japanese central pathology cohort study ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.